BRUCE C. McLEOD, M.D.; RICHARD J. SASSETTI, M.D.; EDMUND R. COLE, Ph.D.; J. PAUL SCOTT, M.D.
Current factor VIII products expose recipients to many donors and hence to a high risk of acquiring blood-borne infections. Plasma-exchange donation of cryoprecipitate can reduce donor exposure by repeatedly obtaining large yields of factor VIII from individual donors. In this study, donor factor VIII levels were stimulated with desmopressin before donation. Mean yield per donation increased from 1399 ± 425 IU in controls to 3818 ± 1350 IU in stimulated donations (p < 0.001), and mean factor VIII concentration in the cryoprecipitate increased from 8.2 ± 3 lU/mL to 24 ± 12 lU/mL (p < 0.001). A new packaging system dispenses assayed aliquots of stimulated cryoprecipitate in plastic vials. The direct cost of production for this material is $.065 per unit. The cryoprecipitate is hemostatically active and convenient to use, and the aggregate yields from sequential donations by stimulated persons are high enough to allow long-term, single-donor support of many adults with hemophilia.
McLEOD BC, SASSETTI RJ, COLE ER, SCOTT JP. A High-Potency, Single-Donor Cryoprecipitate of Known Factor VIII Content Dispensed in Vials. Ann Intern Med. ;106:35–40. doi: 10.7326/0003-4819-106-1-35
Download citation file:
Published: Ann Intern Med. 1987;106(1):35-40.
Coagulopathies, Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use